Eupraxia Pharmaceuticals Completes C$14.7 million Overnight Marketed Offering
VICTORIA BC — Eupraxia Pharmaceuticals Inc. (“Eupraxia” or the “Company”) (TSX: EPRX), a Phase 2 clinical-stage biotechnology company with an innovative drug delivery technology platform, today announced that it has… Read More




